VanEck Biotech ETF (NASDAQ:BBH) Sees Large Increase in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 2,900 shares, a growth of 107.1% from the January 15th total of 1,400 shares. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is presently 0.3 days.

VanEck Biotech ETF Stock Down 0.7 %

BBH stock opened at $160.56 on Friday. The business has a fifty day moving average price of $161.38 and a 200 day moving average price of $169.95. VanEck Biotech ETF has a fifty-two week low of $151.35 and a fifty-two week high of $183.64.

VanEck Biotech ETF Announces Dividend

The firm also recently announced a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were paid a $1.2517 dividend. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BBH. Truist Financial Corp raised its holdings in VanEck Biotech ETF by 3.8% during the 2nd quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after purchasing an additional 100 shares during the last quarter. Kovitz Investment Group Partners LLC raised its stake in shares of VanEck Biotech ETF by 4.6% during the third quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after buying an additional 141 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in VanEck Biotech ETF in the fourth quarter valued at approximately $32,000. Flagship Harbor Advisors LLC boosted its stake in VanEck Biotech ETF by 12.1% in the fourth quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock valued at $311,000 after acquiring an additional 214 shares during the last quarter. Finally, Truvestments Capital LLC bought a new stake in shares of VanEck Biotech ETF during the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.